HRP20140663T1 - FARMACEUTSKA KOMBINACIJA 3(3-DIMETILAMINO-1-ETIL-2-METIL-PROPIL)-FENOLA I ANTIEPILEPTIÄŚKOG SREDSTVA\n - Google Patents
FARMACEUTSKA KOMBINACIJA 3(3-DIMETILAMINO-1-ETIL-2-METIL-PROPIL)-FENOLA I ANTIEPILEPTIÄŚKOG SREDSTVA\n Download PDFInfo
- Publication number
- HRP20140663T1 HRP20140663T1 HRP20140663AT HRP20140663T HRP20140663T1 HR P20140663 T1 HRP20140663 T1 HR P20140663T1 HR P20140663A T HRP20140663A T HR P20140663AT HR P20140663 T HRP20140663 T HR P20140663T HR P20140663 T1 HRP20140663 T1 HR P20140663T1
- Authority
- HR
- Croatia
- Prior art keywords
- dimethylamino
- phenol
- propyl
- ethyl
- methyl
- Prior art date
Links
- KWTWDQCKEHXFFR-UHFFFAOYSA-N 3-[1-(dimethylamino)-2-methylpentan-3-yl]phenol Chemical compound CN(C)CC(C)C(CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-UHFFFAOYSA-N 0.000 title claims 2
- 239000001961 anticonvulsive agent Substances 0.000 title claims 2
- 230000003556 anti-epileptic effect Effects 0.000 title 1
- 208000002193 Pain Diseases 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 239000002552 dosage form Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 claims 3
- KWTWDQCKEHXFFR-RISCZKNCSA-N 3-[(2s,3s)-1-(dimethylamino)-2-methylpentan-3-yl]phenol Chemical compound CN(C)C[C@@H](C)[C@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-RISCZKNCSA-N 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- KWTWDQCKEHXFFR-FZMZJTMJSA-N 3-[(2r,3s)-1-(dimethylamino)-2-methylpentan-3-yl]phenol Chemical compound CN(C)C[C@H](C)[C@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-FZMZJTMJSA-N 0.000 claims 1
- KWTWDQCKEHXFFR-BXUZGUMPSA-N 3-[(2s,3r)-1-(dimethylamino)-2-methylpentan-3-yl]phenol Chemical compound CN(C)C[C@@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-BXUZGUMPSA-N 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 229960001948 caffeine Drugs 0.000 claims 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims 1
- 229960000623 carbamazepine Drugs 0.000 claims 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229960002623 lacosamide Drugs 0.000 claims 1
- VPPJLAIAVCUEMN-GFCCVEGCSA-N lacosamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1 VPPJLAIAVCUEMN-GFCCVEGCSA-N 0.000 claims 1
- 229960001848 lamotrigine Drugs 0.000 claims 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims 1
- 229960004002 levetiracetam Drugs 0.000 claims 1
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229960003312 retigabine Drugs 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 229960004394 topiramate Drugs 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Claims (15)
1. Kombinacija naznačena time da kao komponentu(e) sadrži:
(a) barem jedan 3-(3-Dimetilamino-1-etil-2-metil-propil)-fenol sa formulom (I),
[image]
proizvoljno u obliku jednog od njegovih stereoizomera, naročito enantiomera ili diastereomera, racemata ili u obliku smjese njegovih stereoizomera, naročito enantiomera i/ili diastereomera u bilo kojem omjeru miješanja, ili bilo koja odgovarajuća kisela adicijska sol, te
(b) barem jedno antiepileptičko sredstvo odabrano iz skupine koja sadrži topiramat, lamotrigin, karbamazepin, lakozamid, levetiracetam i retigabin.
2. Kombinacija prema zahtjevu 1, naznačena time da je spoj sa formulom (I) odabran od
(1R,2R)-3-(3-Dimetilamino-1-etil-2-metil-propil)-fenola,
(1S,2S)-3-(3-Dimetilamino-1-etil-2-metil-propil)-fenola,
(1R,2S)-3-(3-Dimetilamino-1-etil-2-metil-propil)-fenola,
(1S,2R)-3-(3-Dimetilamino-1-etil-2-metil-propil)-fenola, te bilo koje njihove smjese.
3. Kombinacija prema zahtjevu 2, naznačena time da je spoj sa formulom (I) odabran od
(1R,2R)-3-(3-Dimetilamino-1-etil-2-metil-propil)-fenola,
(1S,2S)-3-(3-Dimetilamino-1-etil-2-metil-propil)-fenola, te bilo koje njihove smjese.
4. Kombinacija prema zahtjevu 2 ili 3, naznačena time da je spoj sa formulom (I) (1R,2R)-3-(3-Dimetilamino-1-etil-2-metil-propil)-fenol sa formulom (I'),
[image]
ili njihova kisela adicijska sol, pri čemu je poželjna hidrokloridna adicijska sol.
5. Kombinacija prema bilo kojem zahtjevu od 1-4, naznačena time da su komponente (a) i (b) prisutne kao sol formirana od tih dviju komponenata.
6. Kombinacija prema bilo kojem zahtjevu od 1-5, naznačena time da su komponente (a) i (b) prisutne u takvom težinskom omjeru da će pripravak imati sinergistički učinak nakon primjene na pacijentu.
7. Farmaceutski pripravak naznačena time da sadrži kombinaciju prema bilo kojem zahtjevu od 1-6 i proizvoljno jedno ili više pomoćnih sredstava.
8. Oblik doziranja naznačen time da sadrži kombinaciju prema bilo kojem zahtjevu od 1- 6 i proizvoljno jedno ili više pomoćnih sredstava.
9. Oblik doziranja prema zahtjevu 8, naznačen time da je pogodan za oralnu, intravenoznu, intraarterijalnu, intraperitonealnu, intradermalnu, transdermalnu, intratekalnu, intramuskularnu, intranazalnu, transmukoznu, subkutanu, ili rektalnu primjenu.
10. Oblik doziranja prema zahtjevu 8 ili 9, naznačen time da jedna ili obje komponente (a) i (b) je/su prisutne u obliku sa kontroliranim otpuštanjem.
11. Oblik doziranja prema bilo kojem zahtjevu od 8-10, naznačen time da dodatno sadrži kofein.
12. Uporaba kombinacije prema bilo kojem zahtjevu od 1-6 naznačena time da je za pripravu lijeka za liječenje boli.
13. Uporaba prema zahtjevu 12, naznačena time da je bol odabrana od upalne boli, neuropatske boli, akutne boli, kronične boli, visceralne boli, bol od migrene i boli od karcinoma
14. Uporaba prema zahtjevu 12 ili 13, naznačena time da je lijek prilagođen za istodobnu ili sekvencijalnu primjenu komponenata (a) i (b), pri čemu se spoj (a) može primjenjivati prije ili poslije spoja (b), te pri čemu se spojevi (a) ili (b) primjenjuju na sisavca bilo istim ili različitim putem primjene.
15. Kombinacija prema bilo kojem zahtjevu od 1-6 naznačena time da je za uporabu kod liječenja boli.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08015625 | 2008-09-05 | ||
| PCT/EP2009/006424 WO2010025931A2 (en) | 2008-09-05 | 2009-09-04 | Pharmaceutical combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140663T1 true HRP20140663T1 (hr) | 2014-10-10 |
Family
ID=40345058
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140663AT HRP20140663T1 (hr) | 2008-09-05 | 2014-07-14 | FARMACEUTSKA KOMBINACIJA 3(3-DIMETILAMINO-1-ETIL-2-METIL-PROPIL)-FENOLA I ANTIEPILEPTIÄŚKOG SREDSTVA\n |
| HRP20190500TT HRP20190500T1 (hr) | 2008-09-05 | 2019-03-13 | Farmaceutska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola i pregabalina ili gabapentina |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190500TT HRP20190500T1 (hr) | 2008-09-05 | 2019-03-13 | Farmaceutska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola i pregabalina ili gabapentina |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US20100063148A1 (hr) |
| EP (2) | EP2331210B1 (hr) |
| JP (4) | JP5731387B2 (hr) |
| KR (3) | KR101641519B1 (hr) |
| CN (2) | CN105520924B (hr) |
| AR (2) | AR073361A1 (hr) |
| AU (3) | AU2009289776A1 (hr) |
| BR (1) | BRPI0920521A2 (hr) |
| CA (1) | CA2735857C (hr) |
| CL (1) | CL2011000317A1 (hr) |
| CO (1) | CO6382142A2 (hr) |
| CY (2) | CY1115751T1 (hr) |
| DK (2) | DK2331210T3 (hr) |
| EC (1) | ECSP11010869A (hr) |
| ES (2) | ES2719900T3 (hr) |
| HK (2) | HK1159011A1 (hr) |
| HR (2) | HRP20140663T1 (hr) |
| HU (1) | HUE043278T2 (hr) |
| IL (3) | IL211135A (hr) |
| LT (1) | LT2735338T (hr) |
| MX (1) | MX2011002339A (hr) |
| PE (5) | PE20142371A1 (hr) |
| PL (2) | PL2331210T3 (hr) |
| PT (2) | PT2735338T (hr) |
| RU (2) | RU2674150C1 (hr) |
| SI (2) | SI2331210T1 (hr) |
| TR (1) | TR201904388T4 (hr) |
| WO (1) | WO2010025931A2 (hr) |
| ZA (1) | ZA201101449B (hr) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7612112B2 (en) | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
| TWI312285B (en) * | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| US20060159743A1 (en) * | 2001-10-25 | 2006-07-20 | Depomed, Inc. | Methods of treating non-nociceptive pain states with gastric retentive gabapentin |
| US20090176882A1 (en) | 2008-12-09 | 2009-07-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
| KR20150003925A (ko) | 2006-06-15 | 2015-01-09 | 유씨비 파르마 게엠베하 | 상승적 항경련 효과를 갖는 약제학적 조성물 |
| US20100190752A1 (en) | 2008-09-05 | 2010-07-29 | Gruenenthal Gmbh | Pharmaceutical Combination |
| SI2331210T1 (sl) * | 2008-09-05 | 2014-10-30 | Gruenenthal Gmbh | Farmacevtska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola in antiepileptika |
| FR2943246B1 (fr) * | 2009-03-19 | 2011-07-29 | Biocodex | Compose pour son utilisation dans le traitement des neuropathies peripheriques |
| JP6133772B2 (ja) * | 2010-06-15 | 2017-05-24 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 痛み治療用の医薬配合物 |
| WO2012003968A1 (en) | 2010-07-06 | 2012-01-12 | Grünenthal GmbH | Novel gastro- retentive dosage forms comprising a gaba analog and an opioid |
| MX2013000946A (es) | 2010-07-30 | 2013-02-27 | Toray Industries | Agente terapeutico o agente profilactico para el dolor neuropatico. |
| EA024193B1 (ru) * | 2011-03-04 | 2016-08-31 | Грюненталь Гмбх | Фармацевтическая композиция на водной основе, предназначенная для парентерального введения тапентадола |
| US11413239B2 (en) * | 2011-07-20 | 2022-08-16 | Torrent Pharmaceuticals Ltd. | Pharmaceutical composition of tapentadol for nasal administration |
| BR112014000969A2 (pt) * | 2011-07-29 | 2017-04-18 | Gruenenthal Gmbh | administração intratecal ou epidural de 3-[(1s,2s)-3-(dimetilamino)- 1-etil-2-metilpropil]fenol |
| US20130310435A1 (en) * | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol |
| US20130310385A1 (en) | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants |
| US9855286B2 (en) * | 2012-05-18 | 2018-01-02 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component |
| US9308196B2 (en) * | 2012-05-18 | 2016-04-12 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam |
| US9345689B2 (en) * | 2012-05-18 | 2016-05-24 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant |
| US9320725B2 (en) * | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid |
| US9320729B2 (en) | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative |
| US8912226B2 (en) * | 2012-05-18 | 2014-12-16 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR |
| JP6360488B2 (ja) * | 2012-11-01 | 2018-07-18 | トレント・ファーマシューティカルズ・リミテッドＴｏｒｒｅｎｔ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｉｍｉｔｅｄ | 非経口投与のためのタペンタドールの薬学的組成物 |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| CN103655523A (zh) * | 2013-12-24 | 2014-03-26 | 南京艾德凯腾生物医药有限责任公司 | 他喷他多组合物 |
| RU2020128323A (ru) | 2015-12-22 | 2020-10-06 | Зодженикс Интернэшнл Лимитед | Фенфлураминовые композиции и способы их получения |
| WO2017112701A1 (en) | 2015-12-22 | 2017-06-29 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| IL290727B2 (en) | 2016-08-24 | 2023-12-01 | Zogenix International Ltd | A formulation for inhibiting the formation of 5–HT 2B agonists and methods of using it |
| US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| KR20190081385A (ko) | 2017-12-29 | 2019-07-09 | 강원대학교산학협력단 | 옥스카바제핀을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물 |
| JP2021526507A (ja) | 2018-05-11 | 2021-10-07 | ゾゲニクス インターナショナル リミテッド | 発作により誘発される突然死を処置するための組成物および方法 |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4389393A (en) | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
| US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
| US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
| US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
| US5472711A (en) | 1992-07-30 | 1995-12-05 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
| US5330761A (en) | 1993-01-29 | 1994-07-19 | Edward Mendell Co. Inc. | Bioadhesive tablet for non-systemic use products |
| US5455046A (en) | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
| US5399362A (en) | 1994-04-25 | 1995-03-21 | Edward Mendell Co., Inc. | Once-a-day metoprolol oral dosage form |
| DE4426245A1 (de) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
| PL213323B1 (pl) * | 1999-08-20 | 2013-02-28 | Ortho Mcneil Pharm Inc | Kompozycja farmaceutyczna i jej zastosowanie |
| AU2003210486B2 (en) * | 2002-01-16 | 2007-06-28 | Endo Pharmaceuticals Inc. | Pharmaceutical composition and method for treating disorders of the central nervous system |
| RU2286151C2 (ru) * | 2002-02-22 | 2006-10-27 | Уорнер-Ламберт Компани Ллс | Комбинации альфа-2-дельта-лиганда с селективным ингибитором циклооксигеназы-2 |
| WO2007005716A2 (en) * | 2005-06-30 | 2007-01-11 | Cinergen, Llc | Methods of treatment and compositions for use thereof |
| WO2007087452A2 (en) * | 2006-01-27 | 2007-08-02 | Theraquest Biosciences, Llc | Abuse resistant and extended release formulations and method of use thereof |
| AU2007247480B8 (en) * | 2006-04-28 | 2013-04-11 | Grunenthal Gmbh | Pharmaceutical combination comprising 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and an NSAID |
| WO2008027442A2 (en) * | 2006-08-30 | 2008-03-06 | Theraquest Biosciences, Llc | Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use |
| BRPI0819451A2 (pt) * | 2007-11-23 | 2017-10-03 | Protect Pharmaceutical Corp | Composição farmacêutica, método para tratar dor, kit farmacêutico, e, uso de uma composição |
| CA2710538A1 (en) * | 2008-01-25 | 2009-07-30 | Xenoport, Inc. | Crystalline form of a (3s)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use |
| SI2331210T1 (sl) * | 2008-09-05 | 2014-10-30 | Gruenenthal Gmbh | Farmacevtska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola in antiepileptika |
-
2009
- 2009-09-04 SI SI200931014T patent/SI2331210T1/sl unknown
- 2009-09-04 ES ES14000597T patent/ES2719900T3/es active Active
- 2009-09-04 JP JP2011525465A patent/JP5731387B2/ja active Active
- 2009-09-04 MX MX2011002339A patent/MX2011002339A/es active IP Right Grant
- 2009-09-04 EP EP09778335.1A patent/EP2331210B1/en active Active
- 2009-09-04 CN CN201510736012.5A patent/CN105520924B/zh not_active Expired - Fee Related
- 2009-09-04 PE PE2014001116A patent/PE20142371A1/es active IP Right Grant
- 2009-09-04 PL PL09778335T patent/PL2331210T3/pl unknown
- 2009-09-04 CA CA2735857A patent/CA2735857C/en not_active Expired - Fee Related
- 2009-09-04 KR KR1020117005044A patent/KR101641519B1/ko active Application Filing
- 2009-09-04 EP EP14000597.6A patent/EP2735338B1/en active Active
- 2009-09-04 TR TR2019/04388T patent/TR201904388T4/tr unknown
- 2009-09-04 BR BRPI0920521A patent/BRPI0920521A2/pt not_active Application Discontinuation
- 2009-09-04 PE PE2011000206A patent/PE20110291A1/es active IP Right Grant
- 2009-09-04 PE PE2014001117A patent/PE20142372A1/es active IP Right Grant
- 2009-09-04 HU HUE14000597A patent/HUE043278T2/hu unknown
- 2009-09-04 PE PE2018003303A patent/PE20190914A1/es unknown
- 2009-09-04 PT PT14000597T patent/PT2735338T/pt unknown
- 2009-09-04 PT PT97783351T patent/PT2331210E/pt unknown
- 2009-09-04 PL PL14000597T patent/PL2735338T3/pl unknown
- 2009-09-04 ES ES09778335.1T patent/ES2513394T3/es active Active
- 2009-09-04 DK DK09778335.1T patent/DK2331210T3/da active
- 2009-09-04 DK DK14000597.6T patent/DK2735338T3/en active
- 2009-09-04 RU RU2014138166A patent/RU2674150C1/ru active
- 2009-09-04 AR ARP090103405A patent/AR073361A1/es not_active Application Discontinuation
- 2009-09-04 AU AU2009289776A patent/AU2009289776A1/en not_active Abandoned
- 2009-09-04 PE PE2014001115A patent/PE20142357A1/es active IP Right Grant
- 2009-09-04 WO PCT/EP2009/006424 patent/WO2010025931A2/en active Application Filing
- 2009-09-04 KR KR1020167018592A patent/KR101730924B1/ko active IP Right Grant
- 2009-09-04 SI SI200931945T patent/SI2735338T1/sl unknown
- 2009-09-04 CN CN200980135117.8A patent/CN102159284B/zh not_active Expired - Fee Related
- 2009-09-04 KR KR1020177010825A patent/KR101851120B1/ko active IP Right Grant
- 2009-09-04 LT LTEP14000597.6T patent/LT2735338T/lt unknown
- 2009-09-04 RU RU2011112444/15A patent/RU2571501C2/ru active
- 2009-09-04 US US12/554,235 patent/US20100063148A1/en not_active Abandoned
-
2011
- 2011-02-09 IL IL211135A patent/IL211135A/en active IP Right Grant
- 2011-02-14 CL CL2011000317A patent/CL2011000317A1/es unknown
- 2011-02-16 CO CO11018461A patent/CO6382142A2/es active IP Right Grant
- 2011-02-23 ZA ZA2011/01449A patent/ZA201101449B/en unknown
- 2011-03-04 EC EC2011010869A patent/ECSP11010869A/es unknown
- 2011-12-13 HK HK11113438.0A patent/HK1159011A1/xx not_active IP Right Cessation
- 2011-12-13 HK HK14111224.9A patent/HK1198145A1/xx not_active IP Right Cessation
-
2014
- 2014-07-14 HR HRP20140663AT patent/HRP20140663T1/hr unknown
- 2014-09-16 CY CY20141100748T patent/CY1115751T1/el unknown
- 2014-12-12 JP JP2014251851A patent/JP2015096530A/ja active Pending
-
2015
- 2015-02-24 IL IL237392A patent/IL237392B/en active IP Right Grant
- 2015-02-24 IL IL237391A patent/IL237391A/en active IP Right Grant
-
2016
- 2016-05-11 AU AU2016203053A patent/AU2016203053B2/en not_active Ceased
- 2016-12-12 JP JP2016240032A patent/JP2017071636A/ja active Pending
-
2018
- 2018-04-26 AU AU2018202879A patent/AU2018202879B2/en not_active Ceased
-
2019
- 2019-03-13 HR HRP20190500TT patent/HRP20190500T1/hr unknown
- 2019-03-27 CY CY20191100357T patent/CY1121492T1/el unknown
- 2019-04-02 JP JP2019070282A patent/JP2019131578A/ja active Pending
- 2019-07-19 AR ARP190102034A patent/AR117613A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140663T1 (hr) | FARMACEUTSKA KOMBINACIJA 3(3-DIMETILAMINO-1-ETIL-2-METIL-PROPIL)-FENOLA I ANTIEPILEPTIÄŚKOG SREDSTVA\n | |
| HRP20151327T1 (hr) | Farmaceutska kombinacija za lijeäśenje boli | |
| HRP20110076T1 (hr) | Farmaceutske kombinacije koje sadrže 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol i paracetamol | |
| HRP20110271T1 (hr) | Farmaceutska kombinacija koja sadrži 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol i nsaid (nesteroidni antiinflamatorni lijek) | |
| HRP20211032T1 (hr) | Postupci za uporabu agonista fxr | |
| KR20230075528A (ko) | 암 치료를 위한 조합 요법 | |
| HRP20161103T1 (hr) | Kemijski spojevi | |
| HRP20140280T1 (hr) | Uporaba 1-fenil-3-dimetilamino-propan spojeva u terapiji neuropatske boli | |
| RU2349323C2 (ru) | Комбинация избирательного ингибитора обратного захвата норадреналина и ингибитора pdev | |
| HRP20140215T1 (hr) | Kombinacija koja sadrži paklitaksel za lijeäśenje raka jajnika | |
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| Jiménez-Andrade et al. | Synergistic effects between codeine and diclofenac after local, spinal and systemic administration | |
| AR063256A1 (es) | Derivados de 4, 5, 6, 7-tetrahidro-imidazo[4, 5, 1-jk][1]benzacepin-2(1h)-ona, una composicion farmaceutica y un aditivo de pienso que los comprenden y el uso de los mismos como medicamento para el tratamiento de enfermedades mediadas por agonistas del adrenoreceptor beta-2. | |
| AR061272A1 (es) | Antagonistas de cgrp | |
| ES2532084T3 (es) | Composiciones de topiramato y métodos para su uso | |
| HRP20170517T1 (hr) | Farmaceutski pripravak koji sadrži (1r,4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-dihidro-3'h-spiro[cikoheksan-1,1'-pirano[3,4,b]indol]-4-amin i antikonvulziv | |
| MX2009005798A (es) | Recuperacion de apoplejia. | |
| JP2009520010A5 (hr) | ||
| AR064543A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
| ITMI20070770A1 (it) | Impiego di dimiracetam nel trattamento del dolore cronico | |
| RU2008110644A (ru) | Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств | |
| EP1610773A2 (en) | Use of compounds for the prevention of drug-induced cell toxicity | |
| CO6400019A1 (es) | Composicion farmaceutica que comprende racetam y carnitina y proceso para su preparacion | |
| HRP20171708T1 (hr) | FARMACEUTSKI PRIPRAVAK KOJI SADRŽI (1R,4R)-6'-FLUORO-N,N-DIMETIL-4-FENIL-4',9'-DIHIDRO-3'H-SPIRO[CIKLOHEKSAN-1,1'-PIRANO [3,4,b]INDOL]-4-AMIN I GABAPENTINOID | |
| AR063819A1 (es) | Pirrolo[1,2-a]imidazoldiona eficaz en el tratamiento de neurotoxicidad periferica inducida por agentes quimioterapeuticos. composiciones farmaceuticas y usos. |